Delek Logistics Partners LP DKL 深 滬
等待開盤 09-17 09:30:00 美东时间
56.26
-0.430
-0.76%
華盛通- 最 高57.15
- 今 開56.80
- 成交量 15.48万股
- 最 低 55.83
- 昨 收 56.69
- 總市值 32.18亿
- 52周最高 60.365
- 市盈率 靜 17.07
- 換手率 0.27%
- 52周最低 37.84
- 委 比 -33.55%
- 總股本 5719.73万
- 歷史最高 60.365
- 量 比 0.73
- 振 幅 2.33%
- 歷史最低 -21.785
- 每 手 1
- 風險率 5.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Delek Logistics Partners Commences Underwritten Public Offering Of $175M Of Common Units
Delek Logistics Partners, LP (NYSE:DKL) ("Delek Logistics") announced today that it has commenced an underwritten public offering of $175 million of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the ...
08-13 04:25
Delek Logistics Partners Raises Quarterly Distribution From $1.130 To $1.135/Unit
Delek Logistics Partners, LP (NYSE:DKL) ("Delek Logistics") today declared its quarterly cash distribution for the second quarter 2026 of $1.135 per common limited partner unit, or $4.54 per common limited partner unit on an annualized basis. The second quarter 2026 cash distribution is payable on A...
07-23 04:43
美股大行评级 | 台积电、联合健康、美国合众银行获多家大行上调目标价；奈飞、直觉外科遭数十家大行下调目标价
今日重点评级关注：摩根大通：维持联合大陆航空"超配"评级，目标价从156美元升至203美元；摩根士丹利：维持联合大陆航空"超配"评级，目标价从185美元升至190美元
07-20 13:49
UBS Initiates Coverage On Delek Logistics Partners with Neutral Rating, Announces Price Target of $56
UBS analyst Manav Gupta initiates coverage on Delek Logistics Partners (NYSE:DKL) with a Neutral rating and announces Price Target of $56.
07-17 20:36
Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
Delek Logistics Partners Q1 EPS $0.60 Misses $0.93 Estimate, Sales $297.466M Beat $241.650M Estimate.
Delek Logistics Partners (NYSE:DKL) reported quarterly earnings of $0.60 per share which missed the analyst consensus estimate of $0.93 by 35.48 percent. This is a 17.81 percent decrease over earnings of $0.73 per share
04-29 18:38
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
